HDAC9 and non-small cell lung carcinoma: Our findings are consistent with a previous report involving the HDAC inhibitor vorinostat and an EGFR TKI gefitinib on non-small cell lung cancer (NSCLC) with the BIM deletion polymorphism where vorinostat was also able to reduce the ratio of exon 3- to exon 4-containing BIM transcripts and thus, resensitized NSCLC cells with BIM deletion polymorphism to gefitinib [9].